A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)

  • STATUS
    Recruiting
  • End date
    Apr 1, 2023
  • participants needed
    3000
  • sponsor
    Qin Ning
Updated on 15 February 2022
fever
ascites
bacterial infection
hepatitis
jaundice
fungal infection
encephalopathy
liver disease
hepatitis b acute
spontaneous bacterial peritonitis
pleuritic pain
gastrointestinal hemorrhage
acute hepatitis

Summary

The AARC China Study is to establish a widely recognized and harmonized standard of patients with HBV-ACLF in the Asia Pacific region.

Description

Acute on chronic liver failure (ACLF) is a clinically critical illness and has been extensively researched around the world. However, there is a potential "communication barrier" in the ACLF study; that is, different countries and regions, or different research collaboration groups, follow different ACLF definitions and related standards, making researchers in this field confuse in understanding the research value of relevant research and interpreting the research results. Important differences exist in the Asia-Pacific region and North America and Europe, such as the etiology, the clinical characteristics of the patient group, the requirements for cirrhosis, and the predisposing factors of the disease, making it necessary for China or the Asia-Pacific region to develop appropriate ACLF diagnosis standards and prognosis. In recent years, Chinese experts have also focused on the research progress of APASL ACLF Research Consortium (AARC) in the Asia-Pacific region. It is found that the AARC standards are more suitable for the diagnosis and treatment of patients with ACLF in China than the Western standards. The ACLF prediction model (TPPM model) established by Professor Qin.N's team predicts that the prognostic efficacy of patients with HBV-ACLF is significantly better than that of Western prognosis. The AARC China Study is to establish a widely recognized and harmonized standard of patients with HBV-ACLF in the Asia Pacific region.

Details
Condition Acute on Chronic Liver Failure, HBV
Treatment No intervention
Clinical Study IdentifierNCT04054037
SponsorQin Ning
Last Modified on15 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Chronic liver disease: Chronic hepatitis B
Acute deterioration of liver function: more than one of the below criteria
development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria)
development of hepatic encephalopathy
development of gastrointestinal hemorrhage
development of jaundice (serum bilirubin greater than or equal to 3mg/dl)
development of bacterial infection
spontaneous bacteremia: positive blood cultures without a source of infection
spontaneous bacterial peritonitis: ascitic fluid polymorphonuclear cells >250/L
lower respiratory tract infections: new pulmonary infiltrate in the presence of: i) at least one respiratory symptom (cough, sputum production, dyspnea, pleuritic pain) with ii) at least one finding on auscultation (rales or crepitation) or one sign of infection (core body temperature >38_C or less than 36_C, shivering, or leukocyte count >10,000/mm3 or <4,000/mm3) in the absence of antibiotics
Clostridium difficile Infection: diarrhea with a positive C. difficile assay
bacterial entero-colitis: diarrhea or dysentery with a positive stool culture for Salmonella, Shigella, Yersinia, Campylobacter, or pathogenic E. coli
soft-tissue/skin Infection: fever with cellulitis
urinary tract infection (UTI): urine white blood cell >15/high-power field with either positive urine gram stain or culture
intra-abdominal infections: diverticulitis, appendicitis, cholangitis, etc
other infections not covered above
fungal infections as a separate category

Exclusion Criteria

Patients who do not have chronic liver disease
Patients who have hepatocellular carcinoma
Patients who admitted for extrahepatic manifestations
Patients who have HIV infection
Patients who admitted for symptomatic control of chronic liver disease, other than acute deterioration of liver function
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note